AgeX Therapeutics, Inc. (AGE)
| Previous close | 0.7300 |
| Open | 0.7100 |
| Bid | 0.7100 x 3000 |
| Ask | 0.7650 x 900 |
| Day's range | 0.6828 - 0.7375 |
| 52-week range | 0.5160 - 1.7700 |
| Volume | |
| Avg. volume | 54,957 |
| Market cap | 27.363M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
ALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s
- Business Wire
AgeX Therapeutics Reports First Quarter 2022 Financial Results
ALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.
- Business Wire
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
ALAMEDA, Calif., March 29, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2021.
